Canada Life’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Canada Life’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,949	Closed	-$47K	–	2813
2019 Q1	$47K	Hold	3,949	–	–	﹤0.01%	2267
2018 Q4	$48K	Buy	+3,949	New	+$54.5K	﹤0.01%	2391

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Canada Life's CNCE Position: Q2 2019 in Review

Canada Life sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 3,949 shares — an estimated $47K sold.

Canada Life first reported a position in CNCE in Q4 2018 and held it in 2 quarters. The position peaked at $48K in Q4 2018. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

Canada Life reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Canada Life sold 3,949 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $47K.
Canada Life first reported a position in Concert Pharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
Canada Life's Concert Pharmaceuticals, Inc. position peaked at $48K in Q4 2018.
87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on Canada Life's 13F filing for Q2 2019, filed 31 Jul 2019.